Almotriptan

CLINICAL USE

Acute relief of migraine

DOSE IN NORMAL RENAL FUNCTION

12.5 mg repeated after 2 hours if migraine
recurs (do not take 2nd dose for the same
attack)
Maximum 25 mg in 24 hours

PHARMACOKINETICS

  • Molecular weight                           :
    469.6 (as malate)
  • %Protein binding                           :
    35
  • %Excreted unchanged in urine     :
    40–50
  • Volume of distribution (L/kg)       :
    195 litres
  • half-life – normal/ESRD (hrs)      :
    3.5/7

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–50 Dose as in normal renal function
    10–30 6.25 mg; maximum daily dose
    12.5 mg. Use with caution

  • <10           :
    6.25 mg; maximum daily dose
    12.5 mg. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :
    Unknown dialysability. Dose as in
    GFR <10 mL/min
  • HD                     :
    Likely dialysability. Dose as in
    GFR <10 mL/min
  • HDF/high flux   :
    Likely dialysability. Dose as in
    GFR <10 mL/min
  • CAV/VVHD      :
    Unknown dialysability. Dose as in
    GFR=10–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antidepressants: possibly increasedserotonergic effects with duloxetine;
    increased serotonergic effects with St
    John’s wort – avoid concomitant use
  • Antifungals: concentration increased byketoconazole (increased risk of toxicity)
  • Ergot alkaloids: increased risk ofvasospasm

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia